ChiCTR2100052109 版本V1.3 版本创建时间2022/04/20 15:03:56 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100052109 

最近更新日期:

Date of Last Refreshed on:

2022-04-20 14:49:29 

注册时间:

Date of Registration:

2021-10-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

两种液体治疗方式在肝切除术中的应用比较

Public title:

Comparison of two fluid therapy methods during hepatectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

两种液体治疗方式在肝切除术中的应用比较

Scientific title:

Comparison of two fluid therapy methods during hepatectomy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

沈棋洪 

研究负责人:

沈棋洪 

Applicant:

Shen Qihong 

Study leader:

Shen Qihong 

申请注册联系人电话:

Applicant telephone:

+86 15088554023

研究负责人电话:

Study leader's
telephone:

+86 15088554023

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

shenqihong1989@163.com

研究负责人电子邮件:

Study leader's E-mail:

shenqihong1989@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省嘉兴市中环南路1882号

研究负责人通讯地址:

浙江省嘉兴市中环南路1882号

Applicant address:

1882 Zhonghuan Road South, Jiaxing, Zhejiang, China

Study leader's address:

1882 Zhonghuan Road South, Jiaxing, Zhejiang, China

申请注册联系人邮政编码:

Applicant postcode:

315800

研究负责人邮政编码:

Study leader's postcode:

315800

申请人所在单位:

嘉兴市第一医院

Applicant's institution:

The First Hospital of Jiaxing

研究负责人所在单位:

嘉兴市第一医院

Affiliation of the Leader:

The First Hospital of Jiaxing

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LS2021-KY-189-02

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

嘉兴市第一医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Jiaxing First Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

钱建萍

Contact Name of the ethic committee:

Qian Jianping

伦理委员会联系地址:

浙江省嘉兴市中环南路1882号

Contact Address of the ethic committee:

1882 Zhonghuan Road South, Jiaxing, Zhejiang, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 15088554023

伦理委员会联系人邮箱:

Contact email of the ethic committee:

shenqihong1989@163.com

研究实施负责(组长)单位:

嘉兴市第一医院

Primary sponsor:

The First Hospital of Jiaxing

研究实施负责(组长)单位地址:

浙江省嘉兴市中环南路1882号

Primary sponsor's address:

1882 Zhonghuan Road South, Jiaxing, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

嘉兴

Country:

China

Province:

Zhejiang

City:

Jiaxing

单位(医院):

嘉兴市第一医院

具体地址:

中环南路1882号

Institution
hospital:

The First Hospital of Jiaxing

Address:

1882 Zhonghuan Road South

经费或物资来源:

嘉兴市支撑学科-麻醉学

Source(s) of funding:

Jiaxing Key Discipiline of Medcine --Anesthesiology

研究疾病:

肝切除术  

Target disease:

hepatectomy

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

主要目的:为随机对照试验,每位纳入研究的患者将随机分入LCVP组(以传统CVP为导向的液体治疗方式)或SVV组(以SVV为导向的液体治疗方式),观察两组患者出血量,手术时间,输血例数及输血量,空气栓塞发生情况,出院时间等指标。探索一种潜在可行的围术期液体治疗方式在肝切除术中的应用疗效。  

Objectives of Study:

Main purpose: As a randomized controlled trial, each patient included in the study will be randomly assigned to the LCVP group (traditional CVP-oriented fluid therapy) or the SVV group (SVV-oriented fluid therapy). Volume, operation time, number of blood transfusion cases and blood transfusion volume, occurrence of air embolism, discharge time and other indicators. To explore the efficacy of a potentially feasible perioperative fluid therapy modality in hepatectomy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.行择期肝切除术的患者;
2.患者知情同意,自愿参加。

Inclusion criteria

1. Patients undergoing elective hepatectomy;
2. Informed consent of the patient and voluntary participation;

排除标准:

1.严重肥胖;
2.术前有合并未经控制的高血压患者;
3.有其他系统的严重合并症;
4.ASA分级大于Ⅲ级;
5.CVP或者SVV未在设定范围内的时间超过5min的患者;
6.术中出现大出血或者术后需要送入ICU继续治疗的患者。

Exclusion criteria:

1. Severe obesity;
2. Patients with uncontrolled hypertension before surgery;
3. Serious comorbidities of other systems;
4. ASA classification is greater than grade III;
5. Patients whose CVP or SVV is not within the set range for more than 5 minutes;
6. Patients with major bleeding during surgery or patients who need to be admitted to ICU for further treatment after surgery.

研究实施时间:

Study execute time:

From 2021-10-01 00:00:00 To 2022-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-10-01 00:00:00 To 2022-05-31 00:00:00

干预措施:

Interventions:

组别:

试验组1

样本量:

37

Group:

Experimental group1

Sample size:

干预措施:

控制中心静脉压

干预措施代码:

Intervention:

Control the central venous pressure

Intervention code:

组别:

试验组2

样本量:

37

Group:

Experimental group2

Sample size:

干预措施:

目标导向输液

干预措施代码:

Intervention:

Target directed infusion

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

嘉兴市第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Hospital of Jiaxing

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

出血量

指标类型:

主要指标

Outcome:

blood loss

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术时间

指标类型:

次要指标

Outcome:

duration of surgery

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

输血人数

指标类型:

次要指标

Outcome:

number of patients requiring transfusion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

输血量

指标类型:

次要指标

Outcome:

transfusion volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

No

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男性

Gender:

Male

随机方法(请说明由何人用什么方法产生随机序列):

沈棋洪 电脑随机法

Randomization Procedure (please state who generates the random number sequence and by what method):

Shen Qihong computer random method

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过发表论文公开; ResMan, http://www.medresman.org.cn。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

publish through article; ResMan, http://www.medresman.org.cn.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-10-17 23:01:34